Study Combining Advanced Ultrasound Imaging and Multi-Omics Analysis to Improve Diagnosis and Treatment of Primary Liver Cancer Including HCC and ICC

What this Trial Is About

Primary liver cancer, including hepatocellular carcinoma HCC and intrahepatic cholangiocarcinoma ICC, is a major cause of cancer-related deaths. This research aims to improve how liver cancer is diagnosed and treated by combining advanced imaging techniques with molecular and genetic analysis. The study focuses on understanding tumor differences at multiple levels to guide precise clinical decisions and better predict patient outcomes. The study uses a multi-modal ultrasonic imaging system that includes conventional ultrasound, superb microvascular imaging SMI, shear wave and strain elastography, and contrast-enhanced ultrasound CEUS. These imaging tests will be conducted at multiple time points before and after surgery or conversion therapy, up to five years. Additionally, tumor tissue and blood samples will be collected to study protein and gene characteristics using photoacoustic imaging PAI and multi-omics analysis. Artificial intelligence AI will be applied to integrate imaging and molecular data to develop models predicting tumor behavior and prognosis. Participants will undergo detailed ultrasound examinations performed by experienced sonographers in specific body positions. Blood and tumor samples will be collected for laboratory analyses. Follow-up visits will occur regularly over several years to monitor tumor progression or treatment outcomes. The main outcome measured is the time until tumor progression or failure to follow up, assessed for up to five years. This comprehensive approach aims to provide new tools for precise diagnosis and personalized treatment planning in liver cancer care.

An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.